GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline
MarketBeat
GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company’s senior vice pre
NYSE:GSK